Fruquintinib inhibits VEGFR kinase activity at the molecular level and VEGFR2/3 phosphorylation at the cellular level, endothelial cell proliferation and lumen formation, tumor angiogenesis, and tumor growth. This evidence concerns the gene KDR and neoplasm.